MUFG Securities EMEA plc Raises Holdings in Cencora, Inc. $COR

MUFG Securities EMEA plc increased its position in shares of Cencora, Inc. (NYSE:COR) by 114.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,957 shares of the company’s stock after purchasing an additional 4,246 shares during the quarter. MUFG Securities EMEA plc’s holdings in Cencora were worth $2,687,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Oakworth Capital Inc. purchased a new stake in shares of Cencora during the fourth quarter worth approximately $26,000. Elyxium Wealth LLC purchased a new stake in shares of Cencora during the fourth quarter worth approximately $27,000. Archer Investment Corp increased its position in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares in the last quarter. IAG Wealth Partners LLC purchased a new stake in shares of Cencora during the third quarter worth approximately $30,000. Finally, Caitlin John LLC purchased a new stake in shares of Cencora during the third quarter worth approximately $31,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Performance

Shares of Cencora stock opened at $265.09 on Tuesday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The business’s fifty day simple moving average is $297.22 and its 200-day simple moving average is $332.99. The firm has a market cap of $51.58 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 1.24 and a beta of 0.59. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same period last year, the company earned $4.42 EPS. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora declared that its board has initiated a stock buyback program on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio is presently 18.40%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price objective on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Morgan Stanley set a $342.00 target price on Cencora in a report on Friday, May 8th. Evercore set a $360.00 target price on Cencora in a report on Wednesday, April 8th. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, Weiss Ratings cut Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $380.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.